Effect of tumor necrosis factor-α antagonism in asthma: a meta-analysis of the published literature

  • Xiaoju Chen (陈晓菊)
  • Liang Xiong (熊亮)
  • Shouming Qin (覃寿明)
  • Wanli Ma (马万里)
  • Qiong Zhou (周 琼)
Article

Summary

It remains controversial whether tumor necrosis factor (TNF)-α antagonism is effective for asthma. This meta-analysis was performed to evaluate efficacy of TNF-α antagonism in treatment of patients with asthma. MEDLINE, EMBASE, LILACS, and CINAHL databases were searched for English-language studies published through January 3, 2010. Randomized-controlled trials comparing TNF-α antagonism with control therapy were selected. For each report, data were extracted in relation to the outcomes analyzed: asthma exacerbation, asthma quality of life questionnaire scores, and forced expiratory volume in 1 second. Four assessable trials were identified including 641 patients with asthma. TNF-α antagonism therapy was superior to control therapy in preventing exacerbations in asthmatics [pooled odds ratio 0.52 (95% confidence interval 0.29–0.88), P=0.02]; however, there was a nonsignificant reduction in asthma quality of life questionnaire scores [0.23 (0 to 0.47), P=0.05], forced expiratory volume in 1 second [0.03, (−0.14 to 0.10), P=0.74] when analyzed using standardized mean differences. TNF-α antagonism was superior to control chemotherapy in terms of asthma exacerbation, but not asthma quality of life questionnaire scores or forced expiratory volume in 1 second.

Key words

asthma immunotherapy Meta-analysis tumor necrosis factor-α 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fanta CH. Asthma. N Engl J Med, 2009,360(10): 1002–1014CrossRefPubMedGoogle Scholar
  2. 2.
    Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol, 2006, 117(3):522–543CrossRefPubMedGoogle Scholar
  3. 3.
    Wenzel S, Szefler SJ. Managing severe asthma. J Allergy Clin Immunol, 2006, 117(3):508–511CrossRefPubMedGoogle Scholar
  4. 4.
    The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J, 2003,22(3): 470–477CrossRefGoogle Scholar
  5. 5.
    Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol, 2007,119(2): 405–413CrossRefPubMedGoogle Scholar
  6. 6.
    Cookson W, Moffatt M. Making sense of asthma genes. N Engl J Med, 2004, 351(17):1794–1796CrossRefPubMedGoogle Scholar
  7. 7.
    Gao J, Shan G, Sun B, et al. Association between polymorphism of tumour necrosis factor alpha-308 gene promoter and asthma: a meta-analysis. Thorax, 2006,61(6): 466–471CrossRefPubMedGoogle Scholar
  8. 8.
    Cembrzynska-Nowak M, Szklarz E, Inglot AD, et al. Elevated release of tumor necrosis factor-alpha and interferon-gamma by bronchoalveolar leukocytes from patients with bronchial asthma. Am Rev Respir Dis, 1993, 147(2):291–295PubMedGoogle Scholar
  9. 9.
    Obase Y, Shimoda T, Mitsuta K, et al. Correlation between airway hyperresponsiveness and airway inflammation in a young adult population: eosinophil, ECP, and cytokine levels in induced sputum. Ann Allergy Asthma Immunol, 2001,86(3):304–310CrossRefPubMedGoogle Scholar
  10. 10.
    Thomas PS, Yates DH, Barnes PJ. Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med, 1995,152(1):76–80PubMedGoogle Scholar
  11. 11.
    Thomas PS, Heywood G. Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax, 2002,57(9):774–778CrossRefPubMedGoogle Scholar
  12. 12.
    Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax, 2005, 60(12):1012–1018CrossRefPubMedGoogle Scholar
  13. 13.
    Rouhani FN, Meitin CA, Kaler M, et al. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Respir Med, 2005,99(9):1175–1182CrossRefPubMedGoogle Scholar
  14. 14.
    Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol, 2002, 31(1):150–153CrossRefPubMedGoogle Scholar
  15. 15.
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996,17(1): 1–12CrossRefPubMedGoogle Scholar
  16. 16.
    Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA, 1995,273(5):408–412CrossRefPubMedGoogle Scholar
  17. 17.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials, 1986,7(3):177–188CrossRefPubMedGoogle Scholar
  18. 18.
    Deeks JJ, Altman D, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG, eds. Systematic reviews in health care. London, UK: BMJ Publishing. 2001:285–312CrossRefGoogle Scholar
  19. 19.
    Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ, 2003,327(7414): 557–560CrossRefPubMedGoogle Scholar
  20. 20.
    Curtin F, Altman DG, Elbourne D. Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. Stat Med, 2002,21(15):2131–2144CrossRefPubMedGoogle Scholar
  21. 21.
    Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med, 2006,354(7):697–708CrossRefPubMedGoogle Scholar
  22. 22.
    Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med, 2006,174(7): 753–762CrossRefPubMedGoogle Scholar
  23. 23.
    Morjaria JB, Chauhan AJ, Babu KS, et al. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax, 2008,63(7): 584–591CrossRefPubMedGoogle Scholar
  24. 24.
    Wenzel SE, Barnes PJ, Bleecker ER, et al. T03 Asthma Investigators. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med, 2009,179(7):549–558CrossRefPubMedGoogle Scholar
  25. 25.
    Global strategy for asthma management and prevention. Global Initiative for Asthma (GINA), 2008. (Accessed August 23, 2009, at http://www.ginasthma.org.)
  26. 26.
    Tantisira KG, Lake S, Silverman ES, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet, 2004, 13(13):1353–1359CrossRefPubMedGoogle Scholar
  27. 27.
    Lazarus SC, Chinchilli VM, Rollings NJ, et al. National Heart Lung and Blood Institute’s Asthma Clinical Research Network. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med, 2007,175(8): 783–790CrossRefPubMedGoogle Scholar
  28. 28.
    Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults: a review. Chest, 2004,125(3):1081–1102CrossRefPubMedGoogle Scholar
  29. 29.
    Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol, 2001, 107(1):3–8CrossRefPubMedGoogle Scholar
  30. 30.
    Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum, 2005, 34(5 Suppl1):7–11CrossRefPubMedGoogle Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Xiaoju Chen (陈晓菊)
    • 1
    • 2
  • Liang Xiong (熊亮)
    • 1
  • Shouming Qin (覃寿明)
    • 3
  • Wanli Ma (马万里)
    • 1
  • Qiong Zhou (周 琼)
    • 1
  1. 1.Department of Respiratory Diseases, Union Hospital, Key Lab of Pulmonary Diseases of Health Ministry, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.The Affiliated Tumor Hospital of Guangxi Medical UniversityNanningChina
  3. 3.First Affiliated HospitalGuangxi Medical UniversityNanningChina

Personalised recommendations